InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright

by · The Cerbat Gem

HC Wainwright reiterated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock.

InflaRx Stock Up 1.9 %

Shares of NASDAQ IFRX opened at $1.57 on Wednesday. The firm has a market cap of $92.45 million, a PE ratio of -2.01 and a beta of 1.57. The business has a 50 day moving average price of $1.49 and a two-hundred day moving average price of $1.50. InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $3.08.

InflaRx (NASDAQ:IFRX – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.04 million. InflaRx had a negative return on equity of 47.03% and a negative net margin of 44,046.09%. On average, analysts anticipate that InflaRx will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC lifted its position in InflaRx (NASDAQ:IFRX – Free Report) by 2.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 704,987 shares of the company’s stock after acquiring an additional 16,383 shares during the quarter. Ikarian Capital LLC owned 1.20% of InflaRx worth $1,086,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

Featured Articles